EU Orphan And Pediatric Proposals Insufficient, Says Industry
Executive Summary
Innovators warn against slashing incentives and argue a lack of a common definition of unmet need is a stumbling block to proposals.
You may also be interested in...
Creating A ‘Critical Mass’: Outgoing EURORDIS Chief On 25 Years Of EU Orphan Disease Policy
As Yann Le Cam prepares to step down from his role as leader of the EU network of rare disease patient organizations, EURORDIS, he reflects on the organization’s role in almost three decades of major changes to Europe’s orphan disease and drug policy.
Long-Awaited EU Review Questions 10-Year Orphan Exclusivity
The EU Orphan Regulation and the Paediatric Regulation have helped to increase the number of products developed for rare diseases and children, but they both have some shortcomings that need to be addressed, according to an evaluation of the legislation carried out by the EU authorities. The European pharmaceutical industry has warned against opening up the legislation, saying it is “critical to maintain a stable and predictable incentives framework."
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.